Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

‘Robustly’ inhibiting glucocorticoid pathway
February 2020
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—ORIC Pharmaceuticals recently presented new preclinical data on ORIC-101, a glucocorticoid receptor (GR) antagonist currently in a Phase 1b clinical trial in combination with nab-paclitaxel in patients with advanced solid tumors. The presentation was at the 2019 San Antonio Breast Cancer Symposium involving a poster titled “ORIC-101 Robustly Inhibits the Glucocorticoid Pathway and Overcomes Chemoresistance in TNBC.”  GR is highly expressed in such cancers as prostate, pancreatic, ovarian, triple-negative breast and endometrial. Studies have indicated that activation of GR reduces the efficacy of chemotherapy, while inhibition of GR with the antagonist ORIC-101 enhances the efficacy of chemotherapy in multiple solid tumor models.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.